Betagistin-Nanoleuk - instructions for use, dose, side effects, contraindications

Excipients: mannitol 25 mg / 50 mg / 75 mg, microcrystalline cellulose 80.8 mg / 161 mg / 242.4 mg, talc 8.7 mg / 17.4 mg / 26.1 mg, silicon dioxide colloid 2.5 mg / 5 mg / 7.5 mg.

Description:

Tablets 8 mg. Round tablets are white.

Tablets 16 mg. Round tablets are white with a risk on one side.

Tablets 24 mg. Round tablets are white with a risk on one side.

Pharmacotherapeutic group:Histamine drug

ATX: & nbsp

N.07.C.A.01 Betagistin

Pharmacodynamics:

Betagistin acts mainly on histamine H₁- and H₃-receptors inner ear and vestibular CNS nuclei. By direct agonistic effects on H₁receptors of the vessels of the inner ear, as well as indirectly through exposure to H₃-receptors improves microcirculation and permeability of capillaries, normalizes the pressure of the endolymph in the labyrinth and cochlea. At the same time betagistin increases blood flow in the basilar artery.

Has a pronounced central effect, being an inhibitor H₃receptors of the nuclei of the vestibular nerve. Improves conductivity in the neurons of the vestibular nuclei at the level of the brainstem.

The clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in noise in the ears, and improvement in hearing in the event of a decrease in it.

Pharmacokinetics:Absorbed quickly, the connection with plasma proteins is low. The maximum concentration in the blood plasma after 3 hours. Half-life after 3-4 hours. It is almost completely excreted by the kidneys in the form of a metabolite (2-peridylacetic acid) for 24 hours.

Indications:

- LPrevention and prevention of vestibular vertigo of various origin;

- syndromes including dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting;

- disease or Meniere's syndrome.

Contraindications:- Hypersensitivity to any of the components of the drug;

- children under 18 years of age (due to lack of data);

- pregnancy and lactation (due to lack of data).

Carefully:

Peptic ulcer of stomach or duodenum (including in anamnesis), pheochromocytoma, bronchial asthma.

These patients should be observed regularly during the treatment period.

Pregnancy and lactation:

There is insufficient data to assess the effects of the drug during pregnancy and lactation. In this regard, not recommended during pregnancy. For the duration of treatment it is necessary to stop breastfeeding.

Dosing and Administration:

Inside, with food.

Tablets 8 mg: 1-2 tablets 3 times a day.

Tablets 16 mg: 1 / 2-1 tablet 3 times a day.

Tablet 24 mg: 1 tablet 2 times a day.

Improvement is usually noted already at the beginning of therapy, a stable therapeutic effect occurs after two weeks of treatment and may increase over several months of treatment. Treatment is long. Duration of drug intake is selected individually.

Side effects:

Gastrointestinal disorders, the emergence of reactions of hypersensitivity from the skin (rash, itching, urticaria), Quincke's edema.

Overdose:

Symptoms: nausea, vomiting, convulsions.

Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.

Interaction:

Cases of interaction or incompatibility with other drugs are unknown.

Effect on the ability to drive transp. cf. and fur:

Betagistin has no sedative effect and does not affect the ability to drive a car or engage in activities requiring rapidity of psychomotor reactions.

Form release / dosage:

Tablets, 8 mg, 16 mg and 24 mg.

Packaging:

Tablets 8 mg

For 10 tablets in a contour mesh package made of PVC / Al foil. 3 contour cellular packs with instructions for use in a cardboard bundle.

Tablets 16 mg and 24 mg

For 15 tablets in a contour mesh box made of PVC / Al foil. 2 contour cellular packs with instructions for use in a cardboard bundle.

Storage conditions:

In a dry, the dark place at a temperature of no higher than 30 ° C.

Keep in original packaging, out of the reach of children.

Shelf life:

2 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LSR-009783/08

Date of registration:08.12.2008 / 23.06.2014

Expiration Date:Unlimited

The owner of the registration certificate:NANOLEC, LTD. NANOLEC, LTD. Russia

Manufacturer: & nbsp

ABDI IBRAHIM ILAC SAN. VE TIC., A.S. Turkey

Representation: & nbspNANOLEC, LTD.NANOLEC, LTD.

Information update date: & nbsp24.01.2017

Illustrated instructions

Instructions

Betagistin-Nanolek (Betahistine-Nanolek)